Compensated Awareness Post View
Disclaimer
CollabRx, Inc. (CLRX) Makes Choosing Cancer Treatments Simpler with Revolutionary App
CollabRx, a leader in cloud-based expert systems to inform healthcare decision making, is harnessing the knowledge of leading physicians, scientists and researchers from the nation’s most prestigious academic and medical institutions to continue development of its CancerRx™ app.
Currently available for download on Apple’s App Store, CancerRx is designed to offer expert guidance for physicians and their patients regarding the complex landscape of oncology therapeutic options. The app provides helpful information on the treatment options for lung cancer, melanoma, metastatic breast cancer and colorectal cancer based on a variety of important clinical parameters.
While treatment options based on current standards of care are presented by the app, it also helps patients and physicians identify the most relevant clinical trials and provides summaries to help users find the most applicable treatment options for their individual needs. In an effort to stay current, CancerRx also presents users with a daily newsfeed from MedPage Today, complete with real-time, over-the-air updates.
As social networks and the internet continue to provide floods of information to patients on how to identify and act upon data that may be relevant to the treatment of a particular cancer, CollabRx is doing its part to eliminate the notable lack of online resources and tools available to provide specific, personalized therapy considerations to physicians and patients. By creating actionable and highly credible information sources, the company is able to best serve its customers who are in the process of determining the best cancer treatment plan.
The company has made big moves in recent weeks, releasing two major public offerings. In the first, CollabRx priced an offering of 3.84 million shares of common stock at $1.25 per share with warrants to purchase up to an aggregate of 3.84 million shares with an exercise price of $1.56. In the second, the company priced 2,362,205 shares of common stock at $1.27 per share, complete with an additional 354,330 shares to cover any over-allotments. Between the two offerings, the company expects gross proceeds of approximately $8.5 million, which could help the company make significant strides toward organizing the world’s knowledge in molecular medicine and making it universally acceptable and useful.
CollabRx works under the principle that optimal healthcare decisions are made when everyone involved has access to the latest and most credible information. Through sustained development of the CancerRx app, as well as continued advancement of its other technologies and platforms, the company is positioning itself to create a significant impact on the future of diagnostics and treatment options for a multitude of life threatening conditions.
For more information, visit www.collabrx.com
